Oxford Expression Technologies Launch Innovative Virus Like Particle Expression Vector

Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, announce the launch of flashBACPRIME, the newest edition to the flashBAC range.

Oxford, UK, November 27, 2012 - Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, announce the launch of flashBACPRIME, the newest edition to the flashBAC range. The new vector is specifically designed to provide increased virus like particle yield and recovery, and also benefits from the traditional ease of use associated with the renowned flashBAC one step baculovirus expression system.

The new vector offers an innovative solution to one of the challenges of VLP production by providing scientists with enhanced recovery and yield. The performance improvement is achieved by inducing cell lysis at a very late stage of infection in Trichoplusia ni (T.ni) derived cell lines. The flashBACPRIME expression vector also offers flexibility for users, although designed for use in virus like particle production, it can also be used for cytoplasmic protein expression and production.

Passing comment, James Bernard, the CEO at Oxford Expression Technologies said, “We are pleased to announce the launch of flashBACPRIME, it represents a significant improvement in performance and we are delighted to offer these benefits to our customers” he continued, “Yield and recovery are an inherent concern with VLP production and our new technology provides scientists with a solution that addresses these concerns, we are also pleased to add another innovation to our highly successful flashBAC range.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression and virus like particle production to visit their website - http://oetltd.com/

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides recombinant protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image:
Media contact - Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Oxford Expression Technologies Launch Revolutionary Baculovirus Extraction and Quantification Kit

Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches baculoQUANT ALL-IN-ONE™, a baculovirus extraction and titration kit.

Oxford, UK, March 26, 2012 - Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, launches baculoQUANT ALL-IN-ONE™, a baculovirus extraction and titration kit. The new kit has been developed together with PCR reagent and equipment specialists Agilent Technologies as a continued theme to provide ease of use to scientists. baculoQUANT ALL-IN-ONE contains all the necessary components for baculovirus extraction and quantification and provides significant advantages over traditional methods.

The new kit represents a significant step forward for baculovirus quantification as it bypasses the need for DNA extraction spin columns, plaque assays, ELISA and immuno assays that current methods rely on. It also boasts a host of new features including viral DNA extraction and titration in less than three hours, less than 1 hour hands on time, increased accuracy and one step DNA extraction.

Passing comment, Richard Broadhead, Sales and Marketing Manager at Oxford Expression Technologies said, “We are pleased to announce the launch of the baculoQUANT ALL-IN-ONE™ baculovirus quantification kit, it represents our continued commitment to provide innovation and ease of use to our customers and scientists involved in recombinant protein expression,” he continued, “We have increased the speed and simplified a key part of any baculovirus workflow, the quantification of virus, we are delighted that our customers can benefit from these improvements.”

Agilent Technologies’ Paige Weis, Manager Custom and Bulk Services commented, “ We are very pleased to collaborate with Oxford Expression Technologies in the development of the new baculoQUANT ALL-IN-ONE™kit, Agilent Technologies is a global leader in PCR technologies and we are delighted to contribute our high performance and easy to use PCR components to this exciting new kit.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression to visit their website - http://oetltd.com/

Agilent Technologies is a world renowned PCR reagent and equipment specialist and one of the world’s premier measurement companies specializing in three key areas, Chemical Analysis, Life Sciences and Electronic Measurement.

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides recombinant protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

Contact:

Mathew Taylor

Director

Algorythm Solutions Ltd

10 Torkington St, Stamford

Lincolnshire PE9 2UY

+44 (0)773 403 2112

mtaylor@algorythmsolutions.com

http://www.algorythmsolutions.com

Oxford Expression Technologies Launches baculoCOMPLETE™

Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, launches its new baculoCOMPLETE™ kit

Oxford, UK, July 18, 2011 - Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, launches its new baculoCOMPLETE™ kit, the all-in-one baculovirus expression kit. The new kit contains all the necessary components for the expression of recombinant proteins in insect cells in a single pack and each kit is capable of producing five recombinant viruses.

As well as containing all of the necessary components for recombinant protein expression, the baculoCOMPLETE™ kit also contains a user guide listing step by step instructions on how to use each component for reproducible high yield recombinant protein production. To cater for new users, an overview on insect cell culture and baculovirus protein expression is also included to complete the all-in-one package.

Passing comment, Richard Broadhead, Sales and Marketing Manager at Oxford Expression Technologies said, “The launch of the baculoCOMPLETE™ all-in-one baculovirus expression kit represents our commitment to provide ease of use to our users and scientists involved in protein expression,” he continued, “Due to the all-in-one nature and informative aspects of the kit, it provides an excellent opportunity and platform for users of other expression systems to easily adopt and benefit from the advantages of baculovirus protein expression.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression to visit their website - http://oetltd.com/

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

Contact:

Mathew Taylor

Director

Algorythm Solutions Ltd

10 Torkington St

Stamford, Lincolnshire PE9 2UY

+44 (0)773 403 2112

mtaylor@algorythmsolutions.com

http://www.algorythmsolutions.com

Oxford Expression Technologies Launches VLP Vaccine Production Services

Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, now applies its expertise to the production of recombinant vaccines, particularly in the field of virus like particle (VLP) vaccines.

Oxford, UK, June 15, 2011 - Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, now applies its expertise to the production of recombinant vaccines, particularly in the field of virus like particle (VLP) vaccines. VLP vaccines represent the next generation of treatment methodologies; the VLP platform offers huge potential for use as a highly effective antiviral vaccine.

The secret to virus like particle vaccines is their ability to mimic the structure of a real virus. After vaccination with these mimics, an individual’s immune response reacts largely as it would to the real virus, but due to the absence of genetic material the VLP vaccine is unable to replicate and is therefore harmless to the vaccinated individual. VLP production requires high yields of multiple virus structural proteins to form complex structures. The expression system needed to produce these structures must be both safe and capable of producing proteins both on a small (testing) and large scale (vaccine production). These requirements are ideally suited to Oxford Expression Technologies highly efficient and scalable baculovirus protein expression system (flashBAC).

Passing comment, Richard Broadhead, Sales and Marketing Manager at Oxford Expression Technologies said, "Baculovirus Expression systems overcome many of the problems associated with VLP production, the FDA has recently licensed a baculovirus produced VLP vaccine for use in humans (Cervarix® by GlaxoSmithKline), paving the way for further baculovirus based VLP production," he continued, "Oxford Expression Technologies is uniquely placed to apply its existing baculovirus expertise to this exciting new field of virus like particle vaccines."

Oxford Expression Technologies invites anyone with an interest in VLP vaccines to please visit their website - http://oetltd.com/articles/news-press/news-stories/vaccine-vlp.html

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image:

Media contact - Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:

Mathew Taylor

Director

Algorythm Solutions Ltd

10 Torkington St

Stamford, Lincolnshire PE9 2UY

+44 (0)773 403 2112

mtaylor@algorythmsolutions.com

http://www.algorythmsolutions.com

Oxford Expression Technologies Launches Optimized Insect Cell Transfection Reagent

Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, has launched baculoFECTIN.

Oxford, UK, April 04, 2011 - Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, has launched baculoFECTIN. This new non-toxic transfection reagent has been optimized for use in insect cells and proven to produce greater levels of transfection - leading to high level protein expression.

The transfection spectrum comprises various established cell lines and primary cells. baculoFECTIN consists of two components, a positively charged polymer with DNA-binding capacity that is embedded into a novel porous nanoparticle. The complete nanoparticle complex protects the bound DNA from degradation by nucleases. Only the DNA nanoparticle complex with its unique size can be preferentially taken up by the cells. Within the cells, the released DNA-nanoparticle complexes are protected against DNA degradation.

"The main benefits of baculoFECTIN compared with lipid-based products are that it has a quick, effective and easy protocol, from co-transfection to high titre seed stock; it is non-toxic so cell health and viability is maintained; and the nanoparticle/polymer duplex optimizes entry into cells and stabilizes the DNA within transfected insect cells," said Richard Broadhead, sales and marketing manager at Oxford Expression Tehnologies. "Stable for up to a year, baculoFECTIN is the perfect companion to our leading baculovirus expression system flashBAC. It is ideal for high-throughput transfection experiments."

For more information, visit: www.oxfordexpression.com

About Oxford Expression Technologies:

Oxford Expression Technologies is a biotechnology company and centre of excellence for baculovirus protein expression. Specializing in the use of the baculovirus expression vector system, a eukaryotic expression system that can express a large variety of recombinant proteins, Oxford Expression Technologies provides protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image: Media contact - Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:

Mathew Taylor

Director

Algorythm Solutions Ltd

10 Torkington St

Stamford, Lincolnshire PE9 2UY

+44 (0)773 403 2112

mtaylor@algorythmsolutions.com

http://www.algorythmsolutions.com